Skip to main content

Table 2 Frequency and odds ratio for anti-VCP1, anti-VCP2, anti-HCP1 and anti-HCP2 antibodies separately and in combinations, in pre-symptomatic individuals and in patients with rheumatoid arthritis (RA) for disease development

From: Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis

Antibodies Antibody frequency in pre-symptomatic individuals (n = 521), % (95 % CI) OR (95 % CI) Sensitivity in patients with RA (n = 241), % (95 % CI) OR (95 % CI) Specificity, % (95 % CI)
VCP1 10.4 (8, 13.3) 6.2 (2.4, 15.6) 36.1 (30.3, 42.3) 30.2 (12.0, 75.9) 98.2 (95.6, 99.3)
VCP2 17.1 (14.1, 20.6) 11.0 (4.4, 27.4) 52.3 (46, 58.5) 58.5 (23.3, 146.8) 98.2 (95.6, 99.3)
HCP1 10.2 (7.9, 13.1) 6.1 (2.4, 15.3) 37.3 (31.5, 43.6) 31.8 (12.7, 80.1) 98.2 (95.6, 99.3)
HCP2 16.3 (13.4, 19.8) 10.4 (4.2, 26.0) 48.5 (42.3, 54.8) 50.4 (20.1, 126.4) 98.2 (95.6, 99.3)
CCP2 36.7 (32.6, 40.9)a 21.9 (10.1, 47.4)a 78.4 (72.8, 83.1) 137.6 (61.2, 309.6) 97.4 (94.6, 98.8)
VCP1 + VCP2 8.6 (6.4, 11.2) 8.5 (2.6, 27.5) 32.8 (27.7, 39.0) 43.7 (13.6, 140.8) 98.9 (96.6, 99.8)
VCP1 + HCP1 1.5 (0.7, 3.1) - 17.0 (12.8, 22.3) 1.21 (1.1, 1.3) 100 (98.3, 100)
VCP1 + HCP2 6.5 (4.7, 9) 18.9 (2.6, 139.0) 28.6 (23.3, 34.7) 108.7 (15.0, 790.0) 99.6 (97.7, 100)
VCP2 + HCP1 3.1 (1.9, 5) - 25.7 (20.6, 31.6) 1.4 (1.3, 1.5) 100 (98.3, 100)
VCP2+ HCP2 11.3 (8.7, 14.2) 17.2 (4.2, 71.1) 40.2 (34.3, 46.6) 90.9 (22.1, 374.2) 99.3 (97.1, 100)
HCP1 + HCP2 5.6 (3.9, 7.9) 8.0 (1.9, 33.6) 26.6 (21.4, 32.5) 48.8 (11.8, 201.9) 99.3 (97.1, 100)
VCP1 + CCP2a 8.7 (6.6, 11.5) 25.8 (3.5, 188.1) 35.7 (29.9, 41.9) 150.4 (20.7, 1090.3) 99.6 (97.7, 100)
VCP2 + CCP2a 15.8 (12.8, 19.1) 25.2 (6.1, 103.2) 52.3 (46, 58.5) 147.9 (36.0, 608.2) 99.3 (97.1, 100)
HCP1 + CCP2a 8.3 (6.2, 11) 24.5 (3.4, 179.2) 35.7 (29.9, 41.9) 150.4 (20.7, 1090.3) 99.6 (97.7, 100)
HCP2 + CCP2a 15.4 (12.6, 18.9) 16.4 (5.1, 52.4) 48.5 (42.3, 54.8) 84.6 (26.4, 271.4) 98.9 (96.6, 99.0)
  1. The antibodies are presented for the frequency of positivity, and with odds ratio (OR) and 95 % confidence interval (95 % CI). aFrequency in pre-symptomatic individuals, n = 518. VCP, viral citrullinated peptides derived from Epstein-Barr-virus encoded protein; HCP, antibodies against histone 4-derived citrullinated peptides, CCP cyclic citrullinated peptide